CureVac NV
NASDAQ:CVAC

Watchlist Manager
CureVac NV Logo
CureVac NV
NASDAQ:CVAC
Watchlist
Price: 2.99 USD 1.01%
Market Cap: 670.7m USD
Have any thoughts about
CureVac NV?
Write Note

CureVac NV
Stock-Based Compensation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CureVac NV
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
CureVac NV
NASDAQ:CVAC
Stock-Based Compensation
€7.7m
CAGR 3-Years
-19%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Stock-Based Compensation
€51.4m
CAGR 3-Years
17%
CAGR 5-Years
46%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Stock-Based Compensation
€20.7m
CAGR 3-Years
-3%
CAGR 5-Years
69%
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Formycon AG
XETRA:FYB
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CureVac NV
Glance View

Market Cap
670.8m USD
Industry
Biotechnology

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

CVAC Intrinsic Value
4.32 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is CureVac NV's Stock-Based Compensation?
Stock-Based Compensation
7.7m EUR

Based on the financial report for Dec 31, 2023, CureVac NV's Stock-Based Compensation amounts to 7.7m EUR.

What is CureVac NV's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 3Y
-19%

Over the last year, the Stock-Based Compensation growth was -16%. The average annual Stock-Based Compensation growth rates for CureVac NV have been -19% over the past three years .

Back to Top